Abstract
Introduction The β-thalassemias are due to autosomal mutations of the β-globin gene, inducing absence or low-level synthesis of β-globin in erythroid cells. It is widely accepted that high production of fetal hemoglobin (HbF) is beneficial for β-thalassemia patients. Sirolimus, also known as rapamycin, is a lipophilic macrolide isolated from a strain of Streptomyces hygroscopicus found to be a strong HbF inducer in vitro and in vivo. In this study, we report biochemical, molecular and clinical results of the sirolimus-based NCT03877809 clinical trial (A Personalized Medicine Approach for β-thalassemia Transfusion Dependent Patients: Testing sirolimus in a First Pilot Clinical Trial: Sirthalaclin).
Methods Accumulation of γ-globin mRNA was analyzed by reverse-transcription-quantitative PCR and the hemoglobin pattern by HPLC. The immunophenotype was analyzed by FACS using antibodies against CD3, CD4, CD8, CD14, CD19, CD25.
Results The results were obtained in 8 patients with β+/β+ and β+/β0 genotypes, treated with a starting dosage of 1 mg/day sirolimus for 24-48 weeks. The first finding of the study was that expression of γ-globin mRNA was increased in blood and erythroid precursor cells isolated from β-thalassemia patients treated with low-dose sirolimus. A second important conclusion of our trial was that sirolimus influences erythropoiesis and reduces biochemical markers associated to ineffective erythropoiesis (I.E.) (excess of free α-globin chains, bilirubin, soluble transferrin receptor and ferritin). In most (7/8) of the patients a decrease of the transfusion demand index was observed. The drug was well tolerated with minor effects on immunophenotype, the only side effect being frequently occurring stomatitis.
Conclusions The data obtained indicate that sirolimus given at low doses modifies hematopoiesis and induces increased expression of γ-globin genes in a sub-set of β-thalassemia patients. Further clinical trials are warranted, considering the possibility to test the drug in patients with less severe forms of the disease and exploring combination therapies.
Competing Interest Statement
The authors declare that they have no competing interests. M.P. is the administrator of Rare Partners srl Impresa Sociale, to whom the rights for the patent WO 2004/004697 on the use of sirolimus in β-thalassemia have been assigned.
Clinical Trial
NCT 03877809
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT03877809
Funding Statement
The sponsor of the trial was Rare Partners srl Impresa Sociale. Supported by Wellcome Trust (United Kingdom, Innovator Award 208872/Z/17/Z), by the UE FP7 THALAMOSS Project (THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia; grant n.306201-FP7-Health-2012-INNOVATION-1) and by AIFA (Agenzia Italiana del Farmaco, Italy, AIFA-2016-02364887).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Ethical Committee in charge of human studies at Arcispedale S. Anna, Ferrara (release of the approval: November 14, 2018).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-first authors
Data Availability
All of the data produced in the present work are contained in the manuscript and in the supplementary material. Other information related to the present study is available upon reasonable request to the authors.
Abbreviations
- Hb
- hemoglobin
- HbA
- adult hemoglobin
- HbF
- fetal hemoglobin
- HPFH
- hereditary persistence of fetal hemoglobin
- TDT
- transfusion-dependent thalassemia
- SCD
- sickle-cell disease
- HU
- hydroxyurea
- mTOR
- mammalian target of rapamycin
- ROS
- reactive oxygen species
- hHSPCs
- Human Hematopoietic Stem and Progenitor Cells
- ErPCs
- erythroid precursor cells
- sTFR
- soluble transferrin receptor
- SLE
- systemic lupus erythematosus
- LAM
- lymphangioleiomyomatosis
- HIV
- human immunodeficiency virus
- HBV
- hepatitis B virus
- HCV
- hepatitis C virus
- FACS
- fluorescence-activated cell sorter
- NGS
- next-generation sequencing
- AEs
- adverse effects
- EU
- European Union
- ODD
- orphan drug designation
- EMA
- European Medicinal Agency
- FDA
- Food and Drug Administration
